STOCK TITAN

Arcturus Therapeutics Holdings Inc. Amended Passive Investment Disclosure

ARK Investment Management LLC and Catherine D. Wood report a 9.19% beneficial stake in Arcturus Therapeutics Holdings Inc. common stock.

Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

ARK Investment Management LLC and Catherine D. Wood report a 9.19% beneficial stake in Arcturus Therapeutics Holdings Inc. common stock. As of December 31, 2025, they together report ownership of 2,611,099 shares, with ARK holding sole voting and dispositive power over these shares.

Catherine D. Wood reports shared voting and dispositive power over the same 2,611,099 shares. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Arcturus. ARK Genomic Revolution ETF is noted as a client with an interest exceeding 5% of the class.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



ARK Investment Management LLC
Signature:/s/ Kellen Carter
Name/Title:Kellen Carter, Chief Compliance Officer
Date:02/03/2026
Catherine D. Wood
Signature:/s/ Catherine D. Wood
Name/Title:Catherine D. Wood, Chief Executive Officer, Chief Investment Officer
Date:02/03/2026

Keep reading